Acetyl Tetrapeptide-9: Mechanism, Dosing & Research Data

Acetyl tetrapeptide-9 is a collagen-stimulating cosmetic peptide that specifically upregulates lumican expression in dermal fibroblasts. By increasing lumican, a SLRP (small leucine-rich proteoglycan) that controls collagen fibril diameter and organization, it restores youthful collagen architecture and improves skin firmness and elasticity. It is marketed under the trade name Collaxyl.

Mechanism of Action

Upregulates lumican mRNA and protein in dermal fibroblasts at low concentrations (0.0001-0.001%)
Lumican (SLRP) controls collagen I fibril diameter; reduced lumican in aged skin leads to collagen fibril heterogeneity and reduced tensile strength
Restoring lumican expression normalizes collagen fibril spacing and diameter in aged dermis, improving mechanical properties
Acetyl group confers improved membrane penetration vs non-acetylated peptide; acetylation at N-terminus protects against aminopeptidase degradation
Secondary effects: modest collagen I synthesis increase likely via improved ECM scaffold organization feedback to fibroblasts

Research Findings

Gene expression profiling: acetyl tetrapeptide-9 increased lumican expression by 150-300% in primary human fibroblasts at 0.0001-0.001%
Electron microscopy: skin treated with 0.001% acetyl tetrapeptide-9 cream for 8 weeks showed normalized collagen fibril diameter distribution vs vehicle
Clinical study: 0.001% acetyl tetrapeptide-9 twice daily for 8 weeks improved skin firmness by 9% and reduced wrinkle volume by 12% vs vehicle by optical profilometry
Combination with Pal-KTTKS (Matrixyl): synergistic improvement in collagen I content and skin biomechanical properties vs either peptide alone
Lumican-null skin equivalent model: acetyl tetrapeptide-9 failed to improve collagen organization in lumican-null system, confirming lumican as the essential mediator

Research Protocols

Cosmetic formulation: 0.0001-0.001% acetyl tetrapeptide-9 in serum or cream; apply twice daily for 8-12 weeks
In vitro: 0.000001-0.001% on fibroblast monolayer for 48-72 hours; measure lumican mRNA by qPCR and protein by ELISA
Combination formulas: commonly paired with palmitoyl pentapeptide-4, palmitoyl tripeptide-5, or vitamin C in anti-aging serums
Profilometry endpoints: Visioscan and FOITS optical surface profilometry at 0 and 8 weeks to quantify wrinkle volume reduction

Interactions

Palmitoyl pentapeptide-4 (Matrixyl): synergistic collagen production via different mechanisms; widely used in combination
Retinol: additive anti-aging effect; retinol works via nuclear receptors while acetyl tetrapeptide-9 works via SLRP upregulation
Hyaluronic acid: commonly co-formulated; HA provides immediate plumping while acetyl tetrapeptide-9 provides structural repair over weeks

Safety Profile

Excellent topical safety. No sensitization detected in HRIPT. No systemic effects at cosmetic concentrations. Non-irritating; suitable for sensitive skin including periorbital area. GRAS for cosmetic use globally.